ABT240705C111000
- 0.01
- 0.000.00%
Abbott Laboratories Newsroom
DexCom (DXCM), Abbott to Launch First FDA Cleared OTC CGMs
Is Abbott Laboratories (ABT) a Good Dividend Growth Stock to Buy and Hold According to Hedge Funds?
TorHoerman Law Advocates for Infants in Pivotal Missouri NEC Trial Against Formula Manufacturers
ST. LOUIS, July 3, 2024 /PRNewswire/ -- TorHoerman Law is set to begin trial on July 8, 2024, in Missouri state court. The case will focus on allegations that cow milk-based baby formula is linked to
Abbott Labs Is Maintained at Outperform by Evercore ISI Group
Abbott Labs Is Maintained at Outperform by Evercore ISI Group
7 Analysts Have This To Say About Abbott Laboratories
Analysts' ratings for Abbott Laboratories (NYSE:ABT) over the last quarter vary from bullish to bearish, as provided by 7 analysts.The following table provides a quick overview of their recent ratings
Abbott Laboratories Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 16.35% Evercore ISI Group $125 → $120 Maintains Outperform 06/04/2024 21.19% RBC Capital $125 →
Evercore Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $120
Evercore analyst Vijay Kumar maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $120.According to TipRanks data, the analyst has a success rate of 47.4% and a
Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $125, Maintains Outperform Rating
Abbott Laboratories (ABT) has an average rating of outperform and price targets ranging from $104 to $143, according to analysts polled by Capital IQ.
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $140
Barclays analyst Matt Miksic maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $140.According to TipRanks data, the analyst has a success rate of 59.5% and a
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Springworks Therapeutics (SWTX)
Barclays Keeps Their Buy Rating on Abbott Laboratories (ABT)
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Did Your Heart Skip a Beat? Your Wearable Knows. -- Barrons.com
By Bill Alpert The day is approaching when your wristwatch may send you to the hospital. The first portable electrocardiograph was an 85-pound backpack. Today, a 10-gram patch stuck on your chest ca
Express News | FDA Says Abbott Medical Issues Correction For HeartMate LVAS System Monitor Due To Screen Issues That Could Cause Unintentional Pump Stop
Express News | FDA: Abbott Heartmate Lvas System Monitor Recall Involves Correcting Devices & Does Not Involve Removing Them From Where They Are Used or Sold
Express News | FDA: There Have Been 14 Reported Injuries, No Reports of Death Related to Recall
Express News | FDA: Abbott Medical Issues Correction for Heartmate Lvas System Monitor Due to Screen Issues That May Cause Unintentional Pump Stop
Investors Heavily Search Abbott Laboratories (ABT): Here Is What You Need to Know
Market Whales and Their Recent Bets on ABT Options
Financial giants have made a conspicuous bullish move on Abbott Laboratories. Our analysis of options history for Abbott Laboratories (NYSE:ABT) revealed 8 unusual trades.Delving into the details, we
Unusual Options Activity: CVS, DKNG and Others Attract Market Bets, CVS V/OI Ratio Reaches 137.5
EST Jun 27th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.